The phase 3 IOB-013/KN-D18 trial (NCT05155254) evaluating IO102-IO103 in combination with pembrolizumab (Keytruda) for the first-line treatment of patients with advanced melanoma will continue without modifications following a recommendation from an independent data monitoring committee (IDMC).
Clinical Trials
Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
Melanoma Treatment Advances: Fianlimab and Cemiplimab Show Promise
A longer-term follow-up of a study evaluating fianlimab, an anti-LAG-3 agent, and cemiplimab (Libtayo), an anti-PD-1 agent, is being presented as a poster at this year’s European Society for Medical Oncology (ESMO) Congress.
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the two regimens: RELATIVITY-047 and CheckMate 067, respectively. No direct comparisons of the regimens in this setting have been reported previously.